In the case of NTRK and ROS1 fusions, the FDA-approved pan-cancer drugs, larotrectinib, and entrectinib are readily available for clinical treatment in these subsets of NPC patients. The gene discussed is ROS1; the disease is nasopharyngeal carcinoma.